Biomarker testing and validation center
Biomarker Developmental Unit
This project is turning lab-discovered antibody markers into reliable blood tests to help find lung and ovarian cancer earlier.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arizona State University-Tempe Campus NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project ID | NIH-11180496 on NIH RePORTER |
What this research studies
Researchers will move antibody-based markers found in earlier work onto a commercial testing platform to make them more consistent and ready for clinical use. The lab will work with a diagnostics company and other centers to optimize, verify, and validate these assays across larger sample sets. The focus is on serological signals — autoantibodies, antibodies to abnormal glycosylated proteins, and antibodies to microbial antigens that differ between cancer and benign disease. They use high-throughput protein array technology to screen many candidate markers and amplify weak early signals from antibody-producing B cells. The goal is to improve and standardize tests that could be used in clinical diagnostic settings.
Who could benefit from this research
Good fit: Ideal participants are people with or at high risk for lung or ovarian cancer or those willing to donate blood or tissue samples for test validation.
Not a fit: People with cancers unrelated to lung or ovarian cancer or those seeking immediate treatment changes are unlikely to get direct benefit from this lab-focused work.
Why it matters
Potential benefit: If successful, this could produce dependable blood tests that help detect lung and ovarian cancers at earlier, more treatable stages.
How similar studies have performed: Some antibody-based early-detection approaches have shown promise in prior studies, but broader clinical adoption is still limited and additional validation is needed.
Where this research is happening
Scottsdale, United States
- Arizona State University-Tempe Campus — Scottsdale, United States (Active)
Researchers
- Principal investigator: Stengelin, Martin — Arizona State University-Tempe Campus
- Study coordinator: Stengelin, Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.